Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 6/20 | 0.61 |
| ▸ | NPC1 | O15118 | 5/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.57 |
| ▸ | MAPT | P10636 | 3/20 | 0.56 |
| ▸ | MEN1 | O00255 | 3/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.56 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.56 |
| ▸ | GFER | P55789 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | THRB | P10828 | 1/20 | 0.51 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23780651 | 0.85 | TAAR1 (0.72) | RAB9ANPC1SMN1; SMN2MAPTMEN1 | |
| SCHEMBL22628619 | 0.83 | RAB9A (0.65) | RAB9ANPC1SMN1; SMN2MAPTMEN1 | |
| SCHEMBL7512302 | 0.83 | RAD52 (0.56) | SMN1; SMN2MAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL14972695 | 0.82 | SYK (0.51) | RAB9ANPC1SMN1; SMN2MAPTMEN1 | |
| SCHEMBL23999931 | 0.82 | RAD52 (0.52) | RAB9ANPC1SMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL21004551 | 0.81 | NFKB1 (0.66) | RAB9ANPC1SMN1; SMN2MAPTMEN1 | |
| SCHEMBL14946746 | 0.79 | RAB9A (0.51) | RAB9ANPC1SMN1; SMN2MAPTMEN1 | |
| SCHEMBL19575358 | 0.79 | AURKA (0.57) | RAB9ANPC1SMN1; SMN2MAPTMEN1 | |
| SCHEMBL11198492 | 0.79 | SYK (0.49) | RAB9ANPC1SMN1; SMN2MAPTMEN1 | |
| Pyrimethanil SCHEMBL20817 | 0.79 | SMN1; SMN2 (0.71) | RAB9ANPC1SMN1; SMN2MAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7329288-B2 | N-heteroaryl secondary para-phenylenediamine, a dye composition comprising such a para-phenylenediamine, a process for preparing this composition and use thereof | L'OREAL S.A. (FR) | 2008-02-12 | — | — | US | claimed |
| US-20060005323-A1 | N-heteroaryl secondary para-phenylenediamine, a dye composition comprising such a para-phenylenediamine, a process for preparing this composition and use thereof | L'OREAL S.A. (FR) | 2006-01-12 | — | — | US | claimed |
| EP-1568694-A1 | N-heteroaryl-para-phenylene diamines for colouring hair | L'OREAL (FR) | 2005-08-31 | — | — | EP | claimed |
| CN-112646758-B | Acinetobacter calcoaceticus and application thereof | 哈尔滨师范大学 | 2022-09-23 | — | — | CN | disclosed |
| CN-112646758-A | Acinetobacter calcoaceticus and application thereof | 哈尔滨师范大学 | 2021-04-13 | — | — | CN | disclosed |
| US-10301203-B2 | Chloroperoxidase-catalyzed degradation of pharmaceutical pollutants in wastewater | THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES (US) | 2019-05-28 | — | — | US | disclosed |
| US-9938176-B1 | Chloroperoxidase-catalyzed degradation of pharmaceutical pollutants in wastewater | THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES (US) | 2018-04-10 | — | — | US | disclosed |
| US-20080176866-A1 | 3-(5-Bromo-2-{4-[5-bromo-4-((1R,2R)-2-hydroxy-1-methyl propylamino)-pyrimidin-2-ylamino]phenylamino}pyrimidin-4-ylamino)butan-2-ol; cell cycle and tyrosine kinase receptor inhibitor; antiproliferative, anticarcinogenic agent | BAYER SCHERING PHARMA AG (DE) | 2008-07-24 | — | — | US | disclosed |
| US-20080176866-A1 | 3-(5-Bromo-2-{4-[5-bromo-4-((1R,2R)-2-hydroxy-1-methyl propylamino)-pyrimidin-2-ylamino]phenylamino}pyrimidin-4-ylamino)butan-2-ol; cell cycle and tyrosine kinase receptor inhibitor; antiproliferative, anticarcinogenic agent | BAYER SCHERING PHARMA AG (DE) | 2008-07-24 | — | — | US | disclosed |
| EP-1939185-A1 | New types of hetaryl-phenylendiamin-pyrimidines as protein kinase inhibitors for the treatment of cancer | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-07-02 | — | — | EP | disclosed |
| WO-2008074515-A1 | NOVEL HETARYL-PHENYLENE-DIAMINE PYRIMIDINE AS PROTEIN KINASE INHIBITORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-06-26 | — | — | WO | disclosed |
| US-7329288-B2 | N-heteroaryl secondary para-phenylenediamine, a dye composition comprising such a para-phenylenediamine, a process for preparing this composition and use thereof | L'OREAL S.A. (FR) | 2008-02-12 | — | — | US | disclosed |
| US-7067549-B2 | Pyrrolidone carboxamides | ACTELION PHARMACEUTICALS AG (CH) | 2006-06-27 | — | — | US | disclosed |
| US-20060005323-A1 | N-heteroaryl secondary para-phenylenediamine, a dye composition comprising such a para-phenylenediamine, a process for preparing this composition and use thereof | L'OREAL S.A. (FR) | 2006-01-12 | — | — | US | disclosed |
| US-20050192292-A1 | Pyrrolidone carboxamides | ACTELION PHARMACEUTICALS AG (CH) | 2005-09-01 | — | — | US | disclosed |
| EP-1568694-A1 | N-heteroaryl-para-phenylene diamines for colouring hair | L'OREAL (FR) | 2005-08-31 | — | — | EP | disclosed |
| EP-1568694-A1 | N-heteroaryl-para-phenylene diamines for colouring hair | L'OREAL (FR) | 2005-08-31 | — | — | EP | disclosed |
| EP-1463724-A1 | PYRROLIDONE CARBOXAMIDES | Actelion Pharmaceuticals Ltd. (CH) | 2004-10-06 | — | — | EP | disclosed |
| WO-2003059905-A1 | PYRROLIDONE CARBOXAMIDES | ACTELION PHARMACEUTICALS LTD (CH) | 2003-07-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050192292-A1 | Pyrrolidone carboxamides | NPY1R, NPY5R, NPY2R | RAB9A 3133/4885NPC1 4071/4885SMN1; SMN2 3678/4885 |
| US-20080176866-A1 | 3-(5-Bromo-2-{4-[5-bromo-4-((1R,2R)-2-hydroxy-1-methyl propylamino)-pyrimidin-2-ylamino]phenylamino}pyrimidin-4-ylamino)butan-2-ol; cell cycle and tyrosine kinase receptor inhibitor; antiproliferative, anticarcinogenic agent | CDK2, MKI67, ERBB2 | RAB9A 4091/4885NPC1 3626/4885SMN1; SMN2 4421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.